[Intravitreal injections: AFSSAPS guide to good practice].
Intravitreal injections are very commonly performed in the daily practice of Ophthalmology and become a leading procedure in the management of age-related macular degeneration, diabetic retinopathy, infectious endophthalmitis or retinitis, uveitis and retinal vein occlusions. Based on the comments of a group of experts, including ophthalmologists, pharmacists and hygienists, the French Agency for the Safety of Health Products (AFSSAPS) edited a guide to good practice of intravitreal injections, revisiting those previously published in 2006. The overall experience accumulated during time is a valuable source of information to determine the most appropriate protocol. Therefore, the simplification of the procedure is reasonably proposed even though safety remains a major issue, in order to avoid complications, especially infections.
Service d'Ophtalmologie, Assistance-Publique Hôpitaux de Paris, CHU Pitié-Salpêtrière, Université Pierre et Marie Curie, 47-83 bd de l'Hôpital, 75013, Paris, France. bahram.bodaghi@psl.aphp.fr
B
B
Bodaghi
J F
JF
Korobelnik
I
I
Cochereau
J
J
Hajjar
F
F
Goebel
N
N
Dumarcet
D052157:Aptamers, Nucleotide / Q000008:administration & dosage; D003930:Diabetic Retinopathy / Q000628:therapy; D009877:Endophthalmitis / Q000628:therapy; D005602:France; D006801:Humans; D058449:Intravitreal Injections / Q000379:methods* / Q000706:statistics & numerical data*; D008268:Macular Degeneration / Q000628:therapy; D013508:Ophthalmologic Surgical Procedures / Q000009:adverse effects / Q000331:legislation & jurisprudence / Q000379:methods / Q000592:standards; D011183:Postoperative Complications / Q000517:prevention & control; D012164:Retinal Diseases / Q000628:therapy; D012170:Retinal Vein Occlusion / Q000628:therapy; D012955:Societies, Medical / Q000331:legislation & jurisprudence
D052157:Aptamers, Nucleotide; C495058:pegaptanib